A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2018
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 07 Jun 2018 Planned primary completion date changed from 30 Apr 2018 to 30 Apr 2019.
- 12 Dec 2017 Planned End Date changed from 1 Aug 2016 to 1 Apr 2023.
- 12 Dec 2017 Planned primary completion date changed from 1 Aug 2016 to 30 Apr 2018.